Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 2Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Carcinoma In Situ 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Thromboembolism 1Thrombocythemia, Essential 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Diseases 1Sezary Syndrome 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms by Site 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

palbociclib 1ipatasertib 1exemestane 1atezolizumab 1Watchful Waiting 1Trabectedin 1Sodium Chloride 1Paclitaxel 1Low-Level Light Therapy 1Gonadotropin-Releasing Hormone 1Floderm topical cream 1Everolimus 1Docetaxel 1Capecitabine 1Botulinum Toxins, Type A 1Anastrozole 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Diseases × Watchful Waiting × Breast × Clear all
NCT04016935 2022-05-17

EndoPredict® Extended Endocrine Trial (EXET)

Myriad Genetic Laboratories, Inc.

Terminated
855 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡